» Articles » PMID: 19245689

Expression of Verotoxin-1 Receptor Gb3 in Breast Cancer Tissue and Verotoxin-1 Signal Transduction to Apoptosis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2009 Feb 28
PMID 19245689
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prerequisite for the potential use of the bacterial toxin verotoxin-1 in the treatment of breast cancer was investigated by first determining the expression of its receptor Gb3 (CD77) in clinical breast cancer tissue specimens. We then examined the cytotoxicity and mechanism of apoptosis induction of Escherichia coli verotoxin-1 (VT-1) in two human breast cancer cell lines.

Methods: Immunohistochemistry for Gb3 expression was performed on cryostat section from 25 breast cancer specimens. The human breast cancer cell lines T47D and MCF-7 were screened for Gb3 expression by flow cytometry. Fluorescein diacetate and LDH release was used to determine cell viability after VT-1 exposure. Apoptosis was studied by measuring caspase activity and DNA-fragmentation. Signal transduction studies were performed on T47D cells with immunoblotting.

Results: Gb3 expression was detected in the vascular endothelial cells of all tumours specimens, and in tumour cells in 17 of the specimens. We found no associations between tumour cell Gb3-expression and age, tumour size, TNM-classification, histological type, hormone receptor expression, or survival time. T47D cells strongly expressed Gb3 and were sensitive to the cytotoxicity, caspase activation and DNA fragmentation by VT-1, whereas MCF-7 cells with faint Gb3-expression were insensitive to VT-1. VT-1 (0.01 - 5 microg/L) exposure for 72 h resulted in a small percentage of viable T47D cells whereas the cytotoxicity of cells pre-treated with 2 micromol/L D, L-treo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP, an inhibitor of glucosylceramide synthesis) was eliminated (< or = 0.1 microg/L VT-1) or reduced (0.5 - 5 microg/L VT-1). VT-1 did not cause cellular LDH-release or cell cycle arrest. VT-1 induction of caspase-3 (0.1, 1, and 5 microg/L VT-1), -8, and -9 (1 and 5 microg/L VT-1) activity and DNA fragmentation of T47D cells was blocked by PPMP. Key components of MAP kinase signalling pathways that control mitochondrial function were investigated. VT-1 0.1 - 5 microg/L induced phosphorylation of JNK as well as MKK3/6 suggesting that survival signal pathways were overruled by VT-1-induced JNK activation leading to mitochondrial depolarization, caspase-9 activation and apoptosis.

Conclusion: The high specificity and apoptosis-inducing properties of verotoxin-1 indicates that the toxin potentially may be used for treatment of Gb3-expressing breast cancer.

Citing Articles

Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy.

Babolhavaeji K, Ahmadi A, Shokoohizadeh L J Cancer Prev. 2025; 29(4):120-128.

PMID: 39790227 PMC: 11706725. DOI: 10.15430/JCP.24.010.


Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research.

Szymczak-Kulus K, Czerwinski M, Kaczmarek R Cell Mol Biol Lett. 2024; 29(1):137.

PMID: 39511480 PMC: 11546571. DOI: 10.1186/s11658-024-00658-7.


Emerging role of MAPK signaling in glycosphingolipid-associated tumorigenesis.

Khamrui E, Banerjee S, Mukherjee D, Biswas K Glycoconj J. 2024; 41(4-5):343-360.

PMID: 39368037 DOI: 10.1007/s10719-024-10168-5.


Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells.

Ito J, Sugawara S, Tatsuta T, Hosono M, Sato M Biomedicines. 2023; 11(8).

PMID: 37626813 PMC: 10452590. DOI: 10.3390/biomedicines11082317.


Genetics of enzymatic dysfunctions in metabolic disorders and cancer.

Mahe M, Rios-Fuller T, Karolin A, Schneider R Front Oncol. 2023; 13:1230934.

PMID: 37601653 PMC: 10433910. DOI: 10.3389/fonc.2023.1230934.


References
1.
De Rosa M, Ackerley C, Wang B, Ito S, Clarke D, Lingwood C . Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J Biol Chem. 2007; 283(8):4501-11. DOI: 10.1074/jbc.M705473200. View

2.
Jia J, Alaoui-El-Azher M, Chow M, Chambers T, Baker H, Jin S . c-Jun NH2-terminal kinase-mediated signaling is essential for Pseudomonas aeruginosa ExoS-induced apoptosis. Infect Immun. 2003; 71(6):3361-70. PMC: 155783. DOI: 10.1128/IAI.71.6.3361-3370.2003. View

3.
Gitig D, Koff A . Cdk pathway: cyclin-dependent kinases and cyclin-dependent kinase inhibitors. Mol Biotechnol. 2001; 19(2):179-88. DOI: 10.1385/MB:19:2:179. View

4.
Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K . Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988; 171(1-2):45-50. DOI: 10.1111/j.1432-1033.1988.tb13756.x. View

5.
Abe A, Inokuchi J, Jimbo M, Shimeno H, NAGAMATSU A, Shayman J . Improved inhibitors of glucosylceramide synthase. J Biochem. 1992; 111(2):191-6. DOI: 10.1093/oxfordjournals.jbchem.a123736. View